IT201600101794A1 - Sequenza nucleotidica esprimente una proteina ancorante esosomi per uso come vaccino. - Google Patents

Sequenza nucleotidica esprimente una proteina ancorante esosomi per uso come vaccino.

Info

Publication number
IT201600101794A1
IT201600101794A1 IT102016000101794A IT201600101794A IT201600101794A1 IT 201600101794 A1 IT201600101794 A1 IT 201600101794A1 IT 102016000101794 A IT102016000101794 A IT 102016000101794A IT 201600101794 A IT201600101794 A IT 201600101794A IT 201600101794 A1 IT201600101794 A1 IT 201600101794A1
Authority
IT
Italy
Prior art keywords
exosome
vaccine
nucleotide sequence
anchoring protein
sequence expressing
Prior art date
Application number
IT102016000101794A
Other languages
English (en)
Italian (it)
Inventor
Maurizio Paolo Maria Federico
Original Assignee
St Superiore Di Sanita
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Superiore Di Sanita filed Critical St Superiore Di Sanita
Priority to IT102016000101794A priority Critical patent/IT201600101794A1/it
Priority to DK17826320.8T priority patent/DK3389701T3/da
Priority to EP17826320.8A priority patent/EP3389701B1/en
Priority to BR112019007343A priority patent/BR112019007343A2/pt
Priority to MX2019004183A priority patent/MX2019004183A/es
Priority to KR1020197013580A priority patent/KR102620487B1/ko
Priority to HUE17826320A priority patent/HUE050492T2/hu
Priority to AU2017343893A priority patent/AU2017343893B2/en
Priority to NZ753370A priority patent/NZ753370B2/en
Priority to IL265942A priority patent/IL265942B2/en
Priority to JP2019540142A priority patent/JP2019536473A/ja
Priority to CN201780076288.2A priority patent/CN110049775A/zh
Priority to RU2019114370A priority patent/RU2761642C2/ru
Priority to ES17826320T priority patent/ES2809212T3/es
Priority to PCT/IT2017/000223 priority patent/WO2018069947A1/en
Priority to CN202310836753.5A priority patent/CN117210480A/zh
Priority to US16/341,042 priority patent/US11559571B2/en
Priority to SG11201903235XA priority patent/SG11201903235XA/en
Priority to CA3040035A priority patent/CA3040035A1/en
Publication of IT201600101794A1 publication Critical patent/IT201600101794A1/it
Priority to JP2022032547A priority patent/JP7340639B2/ja
Priority to US18/157,534 priority patent/US20230364211A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT102016000101794A 2016-10-11 2016-10-11 Sequenza nucleotidica esprimente una proteina ancorante esosomi per uso come vaccino. IT201600101794A1 (it)

Priority Applications (21)

Application Number Priority Date Filing Date Title
IT102016000101794A IT201600101794A1 (it) 2016-10-11 2016-10-11 Sequenza nucleotidica esprimente una proteina ancorante esosomi per uso come vaccino.
IL265942A IL265942B2 (en) 2016-10-11 2017-10-11 A nucleotide sequence expressing an exosome anchor protein for use as a component
RU2019114370A RU2761642C2 (ru) 2016-10-11 2017-10-11 Нуклеотидная последовательность, экспрессирующая якорный белок экзосом для применения в качестве вакцины
BR112019007343A BR112019007343A2 (pt) 2016-10-11 2017-10-11 sequência de nucleotídeos expressando uma proteína de ancoragem de exossomo para uso como vacina
MX2019004183A MX2019004183A (es) 2016-10-11 2017-10-11 Secuencia de nucleotidos que expresa una proteina de anclaje a exosoma para su uso como vacuna.
KR1020197013580A KR102620487B1 (ko) 2016-10-11 2017-10-11 백신으로 사용하기 위한 엑소좀-앵커링 단백질을 발현하는 뉴클레오티드 서열
HUE17826320A HUE050492T2 (hu) 2016-10-11 2017-10-11 Exoszómát horgonyzó fehérjét expresszáló nukleotid-szekvencia vakcinaként történõ alkamazásra
AU2017343893A AU2017343893B2 (en) 2016-10-11 2017-10-11 Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine
NZ753370A NZ753370B2 (en) 2017-10-11 Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine
DK17826320.8T DK3389701T3 (da) 2016-10-11 2017-10-11 Nucleotidesekvens, der udtrykker et exosomforankrende, protein til anvendelse som vaccine
JP2019540142A JP2019536473A (ja) 2016-10-11 2017-10-11 ワクチンとして使用するためのエキソソームアンカータンパク質を発現するヌクレオチド配列
CN201780076288.2A CN110049775A (zh) 2016-10-11 2017-10-11 用作疫苗的表达外泌体锚定蛋白的核苷酸序列
EP17826320.8A EP3389701B1 (en) 2016-10-11 2017-10-11 Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine
ES17826320T ES2809212T3 (es) 2016-10-11 2017-10-11 Secuencia de nucleótidos que expresa una proteína de anclaje al exosoma para usar como vacuna
PCT/IT2017/000223 WO2018069947A1 (en) 2016-10-11 2017-10-11 Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine
CN202310836753.5A CN117210480A (zh) 2016-10-11 2017-10-11 用作疫苗的表达外泌体锚定蛋白的核苷酸序列
US16/341,042 US11559571B2 (en) 2016-10-11 2017-10-11 Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine
SG11201903235XA SG11201903235XA (en) 2016-10-11 2017-10-11 Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine
CA3040035A CA3040035A1 (en) 2016-10-11 2017-10-11 Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine
JP2022032547A JP7340639B2 (ja) 2016-10-11 2022-03-03 ワクチンとして使用するためのエキソソームアンカータンパク質を発現するヌクレオチド配列
US18/157,534 US20230364211A1 (en) 2016-10-11 2023-01-20 Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102016000101794A IT201600101794A1 (it) 2016-10-11 2016-10-11 Sequenza nucleotidica esprimente una proteina ancorante esosomi per uso come vaccino.

Publications (1)

Publication Number Publication Date
IT201600101794A1 true IT201600101794A1 (it) 2018-04-11

Family

ID=58609653

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102016000101794A IT201600101794A1 (it) 2016-10-11 2016-10-11 Sequenza nucleotidica esprimente una proteina ancorante esosomi per uso come vaccino.

Country Status (17)

Country Link
US (2) US11559571B2 (enExample)
EP (1) EP3389701B1 (enExample)
JP (2) JP2019536473A (enExample)
KR (1) KR102620487B1 (enExample)
CN (2) CN117210480A (enExample)
AU (1) AU2017343893B2 (enExample)
BR (1) BR112019007343A2 (enExample)
CA (1) CA3040035A1 (enExample)
DK (1) DK3389701T3 (enExample)
ES (1) ES2809212T3 (enExample)
HU (1) HUE050492T2 (enExample)
IL (1) IL265942B2 (enExample)
IT (1) IT201600101794A1 (enExample)
MX (1) MX2019004183A (enExample)
RU (1) RU2761642C2 (enExample)
SG (1) SG11201903235XA (enExample)
WO (1) WO2018069947A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600101794A1 (it) 2016-10-11 2018-04-11 St Superiore Di Sanita Sequenza nucleotidica esprimente una proteina ancorante esosomi per uso come vaccino.
IT202000009688A1 (it) 2020-05-04 2021-11-04 Biovelocita S R L Proteine di fusione di ancoraggio a esosomi
WO2021224429A1 (en) 2020-05-06 2021-11-11 Biovelocita S.R.L Exosome-anchoring coronavirus fusion proteins and vaccines
IT202000030740A1 (it) * 2020-12-14 2022-06-14 St Superiore Di Sanita SEQUENZA NUCLEOTIDICA ESPRIMENTE UNA PROTEINA ANCORANTE VESCICOLE EXTRACELLULARI FUSA AD ANTIGENI DI SARS-CoV-2 E RELATIVA PROTEINA DI FUSIONE PER L’USO COME VACCINO

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534285B1 (en) * 1984-12-24 2003-03-18 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
FR2928926B1 (fr) 2008-03-18 2015-08-21 Centre Nat Rech Scient Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes
WO2011119628A2 (en) * 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
US20130101614A1 (en) 2010-06-15 2013-04-25 The Regents Of The University Of California Novel live recombinant booster vaccine against tuberculosis
US10004793B2 (en) 2014-04-24 2018-06-26 Statens Serum Institut M.tuberculosis vaccines
IT201600101794A1 (it) 2016-10-11 2018-04-11 St Superiore Di Sanita Sequenza nucleotidica esprimente una proteina ancorante esosomi per uso come vaccino.
IT201600131935A1 (it) 2016-12-29 2018-06-29 Enea Agenzia Naz Per Le Nuove Tecnologie Lenergia E Lo Sviluppo Economico Sostenibile Sequenza segnale di proteina vegetale come coadiuvante in vaccini a DNA.
US11130787B2 (en) 2020-06-11 2021-09-28 MBF Therapeutics, Inc. Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods
CN112409496B (zh) 2020-11-26 2021-07-13 焦顺昌 一种跨膜表达新型冠状病毒抗原s2的融合蛋白、重组载体、重组树突状细胞及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DI BONITO PAOLA ET AL: "HPV-E7 Delivered by Engineered Exosomes Elicits a Protective CD8(+) T Cell-Mediated Immune Response", VIRUSES-BASEL, vol. 7, no. 3, March 2015 (2015-03-01), pages 1079 - 1099, XP002772906, ISSN: 1999-4915 *
KROHN K ET AL: "A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies", MICROBES AND INFECTION 200511 FR, vol. 7, no. 14, November 2005 (2005-11-01), pages 1405 - 1413, XP027845937, ISSN: 1286-4579 *
LATTANZI LAURA ET AL: "A strategy of antigen incorporation into exosomes: Comparing cross-presentation levels of antigens delivered by engineered exosomes and by lentiviral virus-like particles", VACCINE, vol. 30, no. 50, November 2012 (2012-11-01), pages 7229 - 7237, XP002772907, ISSN: 0264-410X *

Also Published As

Publication number Publication date
WO2018069947A8 (en) 2019-07-04
HUE050492T2 (hu) 2020-12-28
CA3040035A1 (en) 2018-04-19
AU2017343893B2 (en) 2024-06-13
IL265942B2 (en) 2023-11-01
JP2022071130A (ja) 2022-05-13
US20230364211A1 (en) 2023-11-16
SG11201903235XA (en) 2019-05-30
JP2019536473A (ja) 2019-12-19
KR20190079628A (ko) 2019-07-05
EP3389701B1 (en) 2020-04-29
WO2018069947A1 (en) 2018-04-19
NZ753370A (en) 2024-01-26
US11559571B2 (en) 2023-01-24
JP7340639B2 (ja) 2023-09-07
CN110049775A (zh) 2019-07-23
AU2017343893A1 (en) 2019-05-30
RU2761642C2 (ru) 2021-12-13
CN117210480A (zh) 2023-12-12
IL265942B1 (en) 2023-07-01
EP3389701A1 (en) 2018-10-24
MX2019004183A (es) 2020-09-03
IL265942A (en) 2019-05-30
RU2019114370A (ru) 2020-11-13
BR112019007343A2 (pt) 2019-10-01
US20200206329A1 (en) 2020-07-02
RU2019114370A3 (enExample) 2021-03-01
KR102620487B1 (ko) 2024-01-03
ES2809212T3 (es) 2021-03-03
DK3389701T3 (da) 2020-08-03

Similar Documents

Publication Publication Date Title
IL263846B (en) Formulation of a peptide vaccine
EP3328394A4 (en) CONCATEMEE peptide epitope RNAs
MA47680A (fr) Arn thérapeutique
MA42134A (fr) Conjugués peptides/oligonucléotides
IL254516B (en) Proteins specific for cd137
DK3723783T3 (da) Mitokondrie-målrettede peptider
DK3393510T5 (da) Zikavirusvaccine
DK3319633T3 (da) Vaccine mod rsv
HUE054551T2 (hu) Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
HUE056166T2 (hu) Új rovargátló fehérjék
HUE055762T2 (hu) Nyújtott hatású készítmények
EP3700558A4 (en) TAU PEPTIDE IMMUNOGENIC CONSTRUCTIONS
EP3355931C0 (en) PROTEIN CONJUGATES
EP3592520C0 (fr) Imprimante 3d béton
IL280678A (en) Cell-penetrating peptides
MA53543A (fr) Vaccins peptidiques
DK3448879T3 (da) Claudin-6 peptider
LT3522905T (lt) Imunogeniniai arginazės peptidai
EP3442990A4 (en) CHIRALE PEPTIDE
EP3463414C0 (en) Protein interfaces
EP3989786A4 (en) A sous vide appliance
ITUA20163193A1 (it) Copolimeri biodegradabili ad uso cosmetico.
IT201600101794A1 (it) Sequenza nucleotidica esprimente una proteina ancorante esosomi per uso come vaccino.
DK3534936T3 (da) Tolerogen dna-vaccine
DK3700922T3 (da) Vesikel, hvori der indgår transmembranprotein